Acumen Pharmaceuticals, Inc.
- ABOS
- NASDAQ
- Biotechnology
- Alzheimer's Disease Drug Development
- Clinical-Stage Biotech
$1.69
Today +1.20%Quote Oct 16, 2026, 08:00 PM UTC
−34.24%over the last month
Max drawdown −37.0%From 1-month high −36.2%3 months −23.5%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$122.2M
Quote Oct 16
Next earnings
Nov 11
Expected, not confirmed
Analyst target
$7.00
+314.2% from here
Floor
—
Data unavailable
Where the price sits
No analyst target range for this stock.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about ABOSPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
No revenue split by segment on file.
Industry
Biotechnology
Employees
61